Market research
SLP Simulations Plus Inc
NASDAQ USD Healthcare
Latest close
As of 07 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 374M
- P/E ratio
- 46.25
- Analyst target
- 18.5
- Dividend yield
- Not available
- Beta
- 1.31
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Health Information Services
- ISIN
- Not available
- Market cap
- 374M
- P/E ratio
- 46.25
- Analyst target
- 18.5
- Dividend yield
- Not available
- Beta
- 1.31
About
About Simulations Plus Inc
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina. As of October 6, 2026, Simulations Plus, Inc. was taken private.
Research context
Simulations Plus Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Health Information Services
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SLP discussion.
5 years, 6 months ago
Simulations Plus, Inc is currently in a long term downtrend where the price is trading 18.6% below its 200 day moving average.
From a valuation standpoint, the stock is 97.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 28.8.
Simulations Plus, Inc's total revenue rose by 13.8% to $11M since the same quarter in the previous year.
Its net income has increased by 20.4% to $2M since the same quarter in the previous year.
Finally, its free cash flow grew by 144.7% to $5M since the same quarter in the previous year.
Based on the above factors, Simulations Plus, Inc gets an overall score of 4/5.